(Q38170011)

30 August 2017

Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities (English)

1 reference

30 August 2017

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sandy R Shultz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Christopher M Hovens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Terence J O'Brien

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

Dennis Velakoulis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Ping Zheng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

10 December 2013

1 reference

30 August 2017

Molecular Neurobiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1532-1539

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12035-013-8601-9

10 June 2020

exact match

0 references

cites work

An update on antiepileptic drugs and suicide: are there definitive answers yet?

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Why mesial temporal lobe epilepsy with hippocampal sclerosis is progressive: uncontrolled inflammation drives disease progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Neuropsychiatric morbidity in focal epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Epilepsy as a spectrum disorder: Implications from novel clinical and basic neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Morphometric abnormalities and hyperanxiety in genetically epileptic rats: a model of psychiatric comorbidity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Chronic temporal lobe epilepsy: a neurodevelopmental or progressively dementing disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Identification of new epilepsy treatments: issues in preclinical methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

The epidemiology and impact of traumatic brain injury: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Treatment of post-traumatic epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Health care costs associated with traumatic brain injury and psychiatric illness in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Psychiatric disturbances after traumatic brain injury: neurobehavioral and personality changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Excitotoxicity in perinatal brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Antioxidant therapies for traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Traumatic brain injury: can the consequences be stopped?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Genetic manipulation of cell death and neuroplasticity pathways in traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Traumatic brain injury: a risk factor for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Epilepsy and cognitive impairments in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Incidence of new-onset seizures in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Post-translational modifications of tau protein: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Protein phosphatases and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Schizosaccharomyces pombe cell division cycle under limited glucose requires Ssp1 kinase, the putative CaMKK, and Sds23, a PP2A-related phosphatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

PKA/AKAP1 and PP2A/Bβ2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Upregulation of astrocytes protein phosphatase-2A stimulates astrocytes migration via inhibiting p38 MAPK in tg2576 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Mild traumatic brain injury: a risk factor for neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Animal models of traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

The role of tau in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

21 January 2018

The many faces of tau

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Substrate-specific reduction of PP2A activity exaggerates tau pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Mitogen-activated protein kinase p38 in HIV infection and associated brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

The effects of lithium on cognition: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Structure of a Protein Phosphatase 2A Holoenzyme: Insights into B55-Mediated Tau Dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Serine/threonine phosphatases: mechanism through structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Epilepsy, neurodegeneration, and extracellular glutamate in the hippocampus of awake and anesthetized rats treated with okadaic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

An okadaic acid-induced model of tauopathy and cognitive deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Impact of injury location and severity on posttraumatic epilepsy in the rat: role of frontal neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8601-9

Potential roles of Cdk5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model.

21 January 2018

1 reference

12 December 2020

The natural history of epilepsy: spontaneous remission and mortality

1 reference

12 December 2020

Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.

1 reference

12 December 2020

Neurochemical sequelae of traumatic brain injury: therapeutic implications

1 reference

12 December 2020

Tau pathology in Alzheimer disease and other tauopathies

1 reference

12 December 2020

Potentiation of tau aggregation by cdk5 and GSK3β

1 reference

12 December 2020

Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice

1 reference

12 December 2020

Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment

1 reference

12 December 2020

Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage

1 reference

12 December 2020

Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology

1 reference

12 December 2020

10.1007/S12035-013-8601-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24323428%20AND%20SRC:MED&resulttype=core&format=json